

November 13th, 2014
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Notice of Revision of the Financial Forecast for FY2014

SymBio today announced a revision of its financial forecast for the fiscal year 2014, previously disclosed on February 12, 2014, to reflect current business fundamentals.

(1) Financial Forecast for Fiscal 2014 (January 1, 2014 to December 31, 2014)

	Net Sales	Operating Profit	Ordinary Profit	Net Profit	Net Profit per Share
	In millions of yen	In millions of yen	In millions of yen	In millions of yen	In millions of yen
Previous Forecast (A)	1,785	(1,654)	(1,650)	(1,654)	(52.63)
Revised Forecast (B)	1,990	(1,311)	(1,308)	(1,311)	(39.50)
Increase/Decrease (B-A)	205	343	342	343	—
Percentage Change (%)	11.5	—	—	—	—
(Reference) Financial results for the previous year ended December, 2013	1,532	(1,680)	(1,601)	(1,605)	(69.29)

(2) Rationale for revision

The sales forecast for FY2014 is expected to be 1,990 million yen, 205 million yen higher than budget, primarily due to an increase of the net sales of TREAKISYM® in overseas. On the other hand, the net loss for FY2014 is expected to be 1,311 million yen, primarily due to lower R&D costs than expected in the budget.

*Any forward-looking statements in this material, including the forecast of financial results, are estimates based on information available at the time and certain assumptions that SymBio's management believes to be reasonable. Actual results may differ substantially from such forecasts due to various factors.

[Contact]

Director, Finance & Accounting
Tetsuya Maruyama
TEL +81(3)5472-1125